BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Costantino L, Barlocco D. New perspectives on the development of antiobesity drugs. Future Medicinal Chemistry 2015;7:315-36. [DOI: 10.4155/fmc.14.167] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Moose JE, Leets KA, Mate NA, Chisholm JD, Hougland JL. An overview of ghrelin O-acyltransferase inhibitors: a literature and patent review for 2010-2019. Expert Opin Ther Pat 2020;30:581-93. [PMID: 32564644 DOI: 10.1080/13543776.2020.1776263] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Vecchiola A, Lagos CF, Carvajal CA, Baudrand R, Fardella CE. Aldosterone Production and Signaling Dysregulation in Obesity. Curr Hypertens Rep 2016;18. [DOI: 10.1007/s11906-016-0626-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
3 Kumar MS. Peptides and Peptidomimetics as Potential Antiobesity Agents: Overview of Current Status. Front Nutr 2019;6:11. [PMID: 30834248 DOI: 10.3389/fnut.2019.00011] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 6.7] [Reference Citation Analysis]
4 Chen HP, Zhao ZZ, Li ZH, Dong ZJ, Wei K, Bai X, Zhang L, Wen CN, Feng T, Liu JK. Novel Natural Oximes and Oxime Esters with a Vibralactone Backbone from the Basidiomycete Boreostereum vibrans. ChemistryOpen 2016;5:142-9. [PMID: 27308232 DOI: 10.1002/open.201500198] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]